This new study by Pandora Pound and Rebecca Ram from Safer Medicines, published in BMJ Open Science, analyses the opinions of scientists who conduct animal studies of stroke. At present there is only one drug available for patients with acute stroke, a ‘clot buster’ called Alteplase (and this drug was not directly dependent upon animal research for its development). Alteplase can only be given to a minority of stroke patients, half of whom will not benefit from it, so there is an urgent need for effective treatments in this area. Given the failure to develop treatments for acute stroke despite decades of animal research in this field, the study aimed to explore scientists’ views about the way forward.
We found that scientists conducting animal studies of stroke agreed that the field was in crisis, and many robustly criticised the science in this area. When it came to identifying the causes of this crisis, most scientists focused on the poor quality of animal studies. Similarly, when it came to solutions, most proposed improving the quality of animal studies in the hope that this would ultimately translate into benefits for stroke patients. A small number of researchers proposed using human in vitro methods alongside animal studies and one proposed using human focused methods instead of animal studies. Although there is evidence then, that a minority of scientists are beginning to consider human focused approaches, our study indicates a strong resistance to relinquishing the use of animal models in stroke research, despite decades of their failure to produce any benefits for stroke patients.
Read the paper in full here
World Patient Safety Day is grounded in the most fundamental principle of medicine – first do no harm “Medication Safety” is the theme for World Patient Safety Day 2022. Safer Medicines Trust is a patient safety charity whose mission is to improve the safety of medicines, so we very much support calls for “Medication Without Harm”. The World […]
The crisis of Alzheimer’s disease research: it’s time to embrace a new approach to help patientsThe problem Alzheimer’s disease (AD) is a leading cause of death in the UK and along with other dementias, is responsible for almost 11% of all deaths in England.1 More than 209,000 new cases are diagnosed each year across the UK.2 It remains a leading cause of death and disability worldwide3, affecting nearly 50 million […]
